rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Stablecoin Development Corporation

SDEV · NYSE American

Health CareBiotechnologyNot moving yet

SDEV stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 35.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 38
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$162K
Officials’ trades on record
0
Institutions holding
20 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$151K$0$125KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months5
Buyers · sellers0 · 5
WhoDidSharesTraded
R01 Fund Lp10% ownersold24,720at $1.0915 Jun 2026filed 17 Jun 2026
Framework Ventures Iv L.p.10% ownersold24,720at $1.0915 Jun 2026filed 17 Jun 2026
Michael John KazleyChief Executive Officersold24,720at $1.0915 Jun 2026filed 17 Jun 2026
Michael John KazleyChief Executive Officerbought53,679,974at $0.8516 Jan 2026filed 19 May 2026
R01 Fund Lp10% ownerbought53,679,974at $0.8516 Jan 2026filed 19 May 2026
Framework Ventures Iv L.p.10% ownerbought50,109,253at $0.8516 Jan 2026filed 19 May 2026
R01 Fund Lp10% ownerbought11,332,020at $0.0016 Oct 2025filed 30 Apr 2026
Framework Ventures Iv L.p.10% ownerbought11,332,020at $0.0016 Oct 2025filed 30 Apr 2026
Michael John KazleyChief Executive Officerbought11,332,020at $0.0016 Oct 2025filed 30 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders20-2 on the quarter
New · exited5 · 6
Reported value$1.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 2026424,695$446K+1,352+0.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026326,988$343K+54,831+20.1%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026281,483$296K-8,786−3.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026131,840$138K+1,056+0.8%
STATE STREET CORPunchanged · filed 7 Aug 2026117,154$123K00.0%
NORTHERN TRUST CORPadded · filed 13 Aug 202659,926$63K+6,250+11.6%
Bank of New York Mellon Corpnew · filed 6 Aug 202628,033$29K+28,033
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 202626,142$27K-56,653−68.4%
State of Wyomingreduced · filed 6 Aug 202623,509$25K-789−3.2%
JANE STREET GROUP, LLCreduced · filed 14 Aug 202622,639$24K-98,465−81.3%

Everyone who traded it

Framework Ventures IV L.P. Company insider10% owner · last 15 Jun 20260 · 1
Framework Ventures Management Llc Company insider10% owner · last 15 Jun 20260 · 1
Michael John Kazley Company insiderChief Executive Officer · last 15 Jun 20260 · 1
R01 Capital Manager Llc Company insider10% owner · last 15 Jun 20260 · 1
R01 Fund LP Company insider10% owner · last 15 Jun 20260 · 1
Paul E. Freiman Company insiderDirector · last 31 Mar 20261 · 2
Swan Sit Company insiderDirector · last 31 Mar 20260 · 0
Tommy Law Company insiderChief Financial Officer · last 31 Mar 20260 · 0
Yenyou Zheng Company insiderDirector · last 31 Mar 20260 · 0
Michael Ernest Anderson Company insider10% owner · last 16 Jan 20260 · 0
David E. Lazar Company insider10% owner · last 21 Oct 20250 · 0
Framework Ventures Iv Gp Llc Company insider10% owner · last 21 Oct 20250 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-107%
Dividend growthFY 2025 · to 31 Dec 20250.0%
Share count trendFY 2025 · to 16 Mar 20265.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$8.0M

Analyst forecasts

No analyst forecasts yet.